Full Press Release Details
BRIDGEWATER, N.J. , May 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis , Chairman and Chief Executive Officer of Insmed, will present at the following virtual investor conferences:
Each presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com . Each webcast will be archived for a period of 30 days following the conclusion of each live event.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE ® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed's earlier-stage clinical pipeline includes brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and treprostinil palmitil, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com .
Argot Partners Laura Perry or Heather Savelle (212) 600-1902 [email protected]
Mandy Fahey Senior Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated